Zacks: Analysts Expect Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Will Announce Quarterly Sales of $520,000.00

Wall Street brokerages expect Infinity Pharmaceuticals, Inc. (NASDAQ:INFIGet Rating) to post $520,000.00 in sales for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Infinity Pharmaceuticals’ earnings. The highest sales estimate is $680,000.00 and the lowest is $200,000.00. Infinity Pharmaceuticals posted sales of $510,000.00 during the same quarter last year, which would indicate a positive year-over-year growth rate of 2%. The business is expected to announce its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Infinity Pharmaceuticals will report full-year sales of $2.05 million for the current year, with estimates ranging from $800,000.00 to $2.70 million. For the next financial year, analysts expect that the company will post sales of $2.17 million, with estimates ranging from $800,000.00 to $3.00 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Infinity Pharmaceuticals.

Infinity Pharmaceuticals (NASDAQ:INFIGet Rating) last released its quarterly earnings results on Tuesday, May 3rd. The biotechnology company reported ($0.14) EPS for the quarter, hitting the consensus estimate of ($0.14). The company had revenue of $0.65 million for the quarter, compared to analyst estimates of $0.40 million. Infinity Pharmaceuticals had a negative return on equity of 175.11% and a negative net margin of 2,254.97%. During the same quarter in the previous year, the company posted ($0.15) earnings per share.

A number of research analysts have recently issued reports on the company. B. Riley dropped their target price on Infinity Pharmaceuticals from $7.00 to $5.00 in a report on Monday, January 24th. Zacks Investment Research raised Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, March 8th. StockNews.com raised Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, May 15th. Piper Sandler dropped their target price on Infinity Pharmaceuticals from $8.00 to $4.00 and set an “overweight” rating on the stock in a report on Tuesday, March 29th. Finally, Truist Financial dropped their price objective on Infinity Pharmaceuticals from $12.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, March 31st. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $6.39.

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. lifted its position in shares of Infinity Pharmaceuticals by 11.4% in the fourth quarter. BlackRock Inc. now owns 6,667,503 shares of the biotechnology company’s stock valued at $15,001,000 after acquiring an additional 684,014 shares in the last quarter. Polar Capital Holdings Plc purchased a new position in Infinity Pharmaceuticals during the third quarter worth about $8,550,000. State Street Corp lifted its position in Infinity Pharmaceuticals by 4.8% during the first quarter. State Street Corp now owns 1,884,979 shares of the biotechnology company’s stock worth $2,149,000 after buying an additional 86,006 shares during the period. Geode Capital Management LLC lifted its position in Infinity Pharmaceuticals by 22.6% during the third quarter. Geode Capital Management LLC now owns 1,734,032 shares of the biotechnology company’s stock worth $5,930,000 after buying an additional 319,114 shares during the period. Finally, Two Sigma Advisers LP lifted its position in Infinity Pharmaceuticals by 45.3% during the third quarter. Two Sigma Advisers LP now owns 1,693,200 shares of the biotechnology company’s stock worth $5,791,000 after buying an additional 527,800 shares during the period. Institutional investors own 54.74% of the company’s stock.

INFI opened at $0.63 on Friday. The firm has a market cap of $55.86 million, a price-to-earnings ratio of -1.23 and a beta of 2.16. Infinity Pharmaceuticals has a 52 week low of $0.46 and a 52 week high of $3.89. The business’s 50 day moving average is $0.88 and its two-hundred day moving average is $1.47.

Infinity Pharmaceuticals Company Profile (Get Rating)

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors.

Featured Stories

Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.